Oncology Central

Focus on maintenance therapy in non-small-cell lung cancer


A major area of controversy in the management of advanced non-small-cell lung cancer (NSCLC) is the role of maintenance therapy. Widely used in the treatment of other solid tumors and hematologic malignancies, maintenance therapy has become a treatment paradigm also for advanced NSCLC only recently due to the introduction in clinical practice of more tolerable drugs, such as pemetrexed, bevacizumab or erlotinib and on the basis of clinical data coming from large Phase III randomized trials.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.